Researchers from The University of Queensland and The Alfred hospital in Melbourne have identified gene variants which may contribute to people being at higher risk for nodular melanoma.
2023
Combination Immunotherapy Effective for Second-Line Melanoma Treatment
A multicenter Phase II clinical trial showed that combination immunotherapy drug therapy with ipilimumab (an anti-CTLA-4 drug) and nivolumab (an anti-PD-1 therapy) is an effective second-line therapy for patients with melanoma that has progressed on PD-1 inhibitors alone.
Dr Spira on the Evaluation of Fianlimab Plus Cemiplimab in Advanced Melanoma
Alexander I. Spira, MD, PhD, FACP, co-director, Virginia Cancer Specialists Research Institute, director, Thoracic and Phase I Program, clinical assistant professor, Johns Hopkins School of Medicine, discusses the evaluation of the LAG-3 inhibitor fianlimab plus cemiplimab-rwlc (Libtayo) in patients with advanced melanoma who were PD-L1 inhibitor–naïve, as seen in the findings from a phase 1 study (NCT03005782).
Adjuvant Nivolumab Approved in Europe for Completely Resected Stage IIB or IIC Melanoma
The European Commission has approved single-agent nivolumab (Opdivo) for use in the adjuvant treatment of adult and adolescent patients aged 12 years or older who have stage IIB or IIC melanoma and who have undergone complete resection.